JZP541

JZP541 is an oral suspension botanical drug derived from the cannabis plant. It is a well-characterized mixture containing various cannabinoids and non-cannabinoid components, including a small amount of tetrahydrocannabinol (THC), the psychoactive component of cannabis. The drug has been developed primarily for the treatment of irritability associated with Autism Spectrum Disorder (ASD) in adults. Its mechanism of action involves modulation of cannabinoid receptors (CB modulators), but further details on specific targets are not provided in available sources. The developer and sponsor for clinical studies is Jazz Pharmaceuticals, often in collaboration with GW Research Ltd. Clinical development reached Phase 2 trials for ASD-related irritability but was terminated before completion[1][2][3][4].